Background: The pandemic coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) influenced millions of lives, not only healthy subjects but also ...
Presentations highlight efzofitimod’s novel myeloid-cell focused mechanism and current Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis. SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. ...
John Carlin (Moderator) – Host, Sarc Fighter Podcast and Co-Chair, FSR Patient Advisory Committee Jim Kuhn – FSR Patient Advocate for Sarcoidosis Shambhu Aryal, M.D. – Medical Director, Inova Lung ...
BASEL, Switzerland & LONDON & NEW YORK--(BUSINESS WIRE)--Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and ...
A research project supported by the National Institutes of Health has developed a tool to rapidly and inexpensively diagnose sarcoidosis, a chronic inflammatory disease marked by the growth of tiny ...
Sarcoidosis develops from inflammation that does not go away and is caused by immune system cells that have clustered together, according to the NHLBI. These clusters form lumps called granulomas in ...
aTyr is developing efzofitimod as a potential therapeutic for patients with fibrotic lung disease. Efzofitimod, a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback